Last reviewed · How we verify
Trastuzumab Emtansine (T-DM1) (trastuzumab-emtansine-t-dm1)
Trastuzumab Emtansine (T-DM1) (generic name: trastuzumab-emtansine-t-dm1) is a Monoclonal antibody drug developed by Pfizer Inc.. It is currently in Phase 2 development.
Trastuzumab emtansine targets HER2-positive cancer cells, delivering a cytotoxic payload that inhibits cell growth and induces apoptosis.
At a glance
| Generic name | trastuzumab-emtansine-t-dm1 |
|---|---|
| Sponsor | Pfizer Inc. |
| Modality | Monoclonal antibody |
| Phase | Phase 2 |
Mechanism of action
Trastuzumab emtansine binds to the HER2 receptor on cancer cells, which triggers the release of a chemotherapy drug inside the cell, leading to cell death. This targeted approach minimizes damage to healthy cells.
Approved indications
Common side effects
- Nausea
- Alopecia
- Diarrhoea
- Fatigue
- FATIGUE
- NAUSEA
- Vomiting
- Constipation
- Anaemia
- HEADACHE
- Arthralgia
- Neutropenia
Key clinical trials
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
- CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy (PHASE2)
- Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread (PHASE1, PHASE2)
- Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib (PHASE2)
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (PHASE2)
- A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors (PHASE2)
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trastuzumab Emtansine (T-DM1) CI brief — competitive landscape report
- Trastuzumab Emtansine (T-DM1) updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI
Frequently asked questions about Trastuzumab Emtansine (T-DM1)
What is Trastuzumab Emtansine (T-DM1)?
How does Trastuzumab Emtansine (T-DM1) work?
Who makes Trastuzumab Emtansine (T-DM1)?
What is the generic name of Trastuzumab Emtansine (T-DM1)?
What development phase is Trastuzumab Emtansine (T-DM1) in?
What are the side effects of Trastuzumab Emtansine (T-DM1)?
Related
- Manufacturer: Pfizer Inc. — full pipeline
- Compare: Trastuzumab Emtansine (T-DM1) vs similar drugs
- Pricing: Trastuzumab Emtansine (T-DM1) cost, discount & access